Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Matthews

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Archives of Disease in Childhood|April 22, 2019
National registry for sudden unexpected deaths of infants and children in England: why do we need one and do families want one?Emma Matthews, Peter Blair, Sanjay Sisodiya, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|February 18, 2020
In vivo assessment of interictal sarcolemmal membrane properties in hypokalaemic and hyperkalaemic periodic paralysisS Veronica Tan, Karen Suetterlin, Roope Männikkö, et al.
Wellcome Open Research|June 10, 2020
Sodium channel myotonia may be associated with high-risk brief resolved unexplained eventsGabriel Cea, Daniel Andreu, Elaine Fletcher, et al.
Pediatric Neurology|June 14, 2023
Care Recommendations for the Investigation and Management of Children With Skeletal Muscle ChannelopathiesEmma Matthews, Jacqueline Palace, Sithara Ramdas, et al.
The Journal of Pediatrics|July 1, 2017
Skeletal Muscle Channelopathies: Rare Disorders with Common Pediatric SymptomsEmma Matthews, Arpana Silwal, Richa Sud, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 4, 2020
Homozygous C-terminal loss-of-function Na<sub>V</sub>1.4 variant in a patient with congenital myasthenic syndromeAndoni Echaniz-Laguna, Valérie Biancalana, Aleksandra Nadaj-Pakleza, et al.
JAMA Neurology|December 15, 2015
Long-term Safety and Efficacy of Mexiletine for Patients With Skeletal Muscle ChannelopathiesKaren Joan Suetterlin, Enrico Bugiardini, Juan P Kaski, et al.
The Lancet. Neurology|September 20, 2024
Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trialVinojini Vivekanandam, Iwona Skorupinska, Dipa L Jayaseelan, et al.
Neurology. Clinical Practice|November 29, 2021
Long-term Safety and Efficacy of Mexiletine in Myotonic Dystrophy Types 1 and 2Christina Mousele, Emma Matthews, Robert D S Pitceathly, et al.
Neuromuscular Disorders : NMD|January 17, 2024
Crossover randomized controlled trial of bumetanide to rescue an attack of exercise induced hand weakness in hypokalaemic periodic paralysisRenata Siciliani Scalco, Jasper M Morrow, Andreea Manole, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Archives of Disease in Childhood|April 22, 2019
National registry for sudden unexpected deaths of infants and children in England: why do we need one and do families want one?Emma Matthews, Peter Blair, Sanjay Sisodiya, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|February 18, 2020
In vivo assessment of interictal sarcolemmal membrane properties in hypokalaemic and hyperkalaemic periodic paralysisS Veronica Tan, Karen Suetterlin, Roope Männikkö, et al.
Wellcome Open Research|June 10, 2020
Sodium channel myotonia may be associated with high-risk brief resolved unexplained eventsGabriel Cea, Daniel Andreu, Elaine Fletcher, et al.
Pediatric Neurology|June 14, 2023
Care Recommendations for the Investigation and Management of Children With Skeletal Muscle ChannelopathiesEmma Matthews, Jacqueline Palace, Sithara Ramdas, et al.
The Journal of Pediatrics|July 1, 2017
Skeletal Muscle Channelopathies: Rare Disorders with Common Pediatric SymptomsEmma Matthews, Arpana Silwal, Richa Sud, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 4, 2020
Homozygous C-terminal loss-of-function Na<sub>V</sub>1.4 variant in a patient with congenital myasthenic syndromeAndoni Echaniz-Laguna, Valérie Biancalana, Aleksandra Nadaj-Pakleza, et al.
JAMA Neurology|December 15, 2015
Long-term Safety and Efficacy of Mexiletine for Patients With Skeletal Muscle ChannelopathiesKaren Joan Suetterlin, Enrico Bugiardini, Juan P Kaski, et al.
The Lancet. Neurology|September 20, 2024
Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trialVinojini Vivekanandam, Iwona Skorupinska, Dipa L Jayaseelan, et al.
Neurology. Clinical Practice|November 29, 2021
Long-term Safety and Efficacy of Mexiletine in Myotonic Dystrophy Types 1 and 2Christina Mousele, Emma Matthews, Robert D S Pitceathly, et al.
Neuromuscular Disorders : NMD|January 17, 2024
Crossover randomized controlled trial of bumetanide to rescue an attack of exercise induced hand weakness in hypokalaemic periodic paralysisRenata Siciliani Scalco, Jasper M Morrow, Andreea Manole, et al.
Pageof 8